

Mehri Salari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1006491/publications.pdf>

Version: 2024-02-01

61
papers

668
citations

686830

13
h-index

676716

22
g-index

72
all docs

72
docs citations

72
times ranked

1189
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (<scp>COVID</scp>â€19) Pandemic. <i>Movement Disorders</i> , 2020, 35, 1095-1096.	2.2	90
2	Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 18.	0.4	39
3	COVID-19-related strokes in adults below 55Âyears of age: a case series. <i>Neurological Sciences</i> , 2020, 41, 1985-1989.	0.9	37
4	COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102915.	0.9	35
5	Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3481-3483.	1.4	28
6	Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction. <i>Neurology: Genetics</i> , 2018, 4, e276.	0.9	26
7	Botulinum Toxin Induced Atrophy: An Uncharted Territory. <i>Toxins</i> , 2018, 10, 313.	1.5	26
8	Cutaneous adverse events related to <scp>COVID</scp> â19 vaccines: A crossâsectional questionnaireâbased study of 867 patients. <i>Dermatologic Therapy</i> , 2022, 35, e15223.	0.8	23
9	Expression Profiling of Blood microRNAs 885, 361, and 17 in the Patients with the Parkinsonâs disease: Integrating Interaction Data to Uncover the Possible Triggering Age-Related Mechanisms. <i>Scientific Reports</i> , 2019, 9, 13759.	1.6	21
10	Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103119.	0.9	18
11	Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial. <i>Journal of Research in Medical Sciences</i> , 2015, 20, 372-8.	0.4	16
12	SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103417.	0.9	16
13	Incidence of anxiety in epilepsy during coronavirus disease (COVID-19) pandemic. <i>Epilepsy and Behavior</i> , 2020, 112, 107442.	0.9	15
14	MiRâ193b deregulation is associated with Parkinson's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6348-6360.	1.6	15
15	Ataxia-telangiectasia-like disorder in a family deficient for MRE11A, caused by a <i>MRE11</i> variant. <i>Neurology: Genetics</i> , 2018, 4, e295.	0.9	13
16	MRI signs of CNS demyelinating diseases. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102665.	0.9	13
17	Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 127-130.	0.9	12
18	Neurological outcome after arterial ischemic stroke in children. <i>Advanced Biomedical Research</i> , 2016, 5, 107.	0.2	12

#	ARTICLE	IF	CITATIONS
19	Fulminant encephalitis as a sole manifestation of COVID-19. <i>Neurological Sciences</i> , 2020, 41, 3027-3029.	0.9	11
20	Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study. <i>Journal of Research in Medical Sciences</i> , 2015, 20, 554.	0.4	10
21	Thalamic Ventral Intermediate Nucleus Deep Brain Stimulation for Orthostatic Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2017, 7, 479.	1.1	10
22	Movement Disorders Associated with COVID-19. <i>Parkinson's Disease</i> , 2021, 2021, 1-11.	0.6	10
23	Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	10
24	Multiple sclerosis among Afghan immigrants in Isfahan, Iran. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 52-57.	0.9	9
25	Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study. <i>BMC Neurology</i> , 2022, 22, 64.	0.8	9
26	Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East. <i>Journal of Parkinson's Disease</i> , 2020, 10, 729-741.	1.5	8
27	Conus medullaris involvement in demyelinating disorders of the CNS: A comparative study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103127.	0.9	8
28	Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-4.	1.4	8
29	Pneumocephalus as a rare complication: a systematic review plus clinical vignette. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 253-268.	0.6	7
30	Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 90-92.	1.1	7
31	Frequency of diencephalic syndrome in NMOs. <i>Acta Neurologica Belgica</i> , 2022, 122, 961-967.	0.5	7
32	Magnetic resonance imaging findings in diagnosis and prognosis of Wilson disease. <i>Journal of Research in Medical Sciences</i> , 2018, 23, 23.	0.4	7
33	Evaluation of non-motor symptoms and their impact on quality of life in patients with Parkinson's disease, Isfahan, Iran. <i>Iranian Journal of Neurology</i> , 2017, 16, 118-124.	0.5	7
34	Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report. <i>BMC Neurology</i> , 2019, 19, 254.	0.8	6
35	Neurological Manifestations and their Correlated Factors in COVID-19 Patients; a Cross-Sectional Study. <i>Archives of Academic Emergency Medicine</i> , 2021, 9, e34.	0.2	6
36	Anti-ma2 receptor encephalitis mimicking Huntington chorea. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 31.	0.4	5

#	ARTICLE	IF	CITATIONS
37	â€œNMDA receptor spectrum disorderâ€•in the differential diagnosis of demyelinating disorders of the CNS: optic neuritis and myelitis. <i>Neurological Sciences</i> , 2021, 42, 151-157.	0.9	4
38	Autoimmune encephalitis: the first observational study from Iran. <i>Neurological Sciences</i> , 2022, 43, 1239-1248.	0.9	4
39	Can COVIDâ€19 accelerate neurodegeneration?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04433.	0.2	4
40	The effect of fampridine on the risk of seizure in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102188.	0.9	4
41	Gastrointestinal dysfunction in idiopathic Parkinsonism: A narrative review. <i>Journal of Research in Medical Sciences</i> , 2016, 21, 126.	0.4	4
42	Deep brain stimulation of anteromedial globus pallidus internus improved OCD rather than tics in a Gilles de la Tourette syndrome patient. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05204.	0.2	4
43	Effect of Disease-Modifying Therapies on Clinical Efficacy of COVID-19 Inactivated Vaccination among People with Multiple Sclerosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
44	Two Cousins with Acute Hemichorea after <sc>BBIBPâ€™CorV</sc> (Sinopharm) <sc>COVID</sc>â€™19 Vaccine. <i>Movement Disorders</i> , 2022, 37, 1101-1103.	2.2	3
45	Diffuse subcortical white matter restriction: An uncommon finding on metronidazole toxicity. <i>Neuroradiology Journal</i> , 2023, 36, 119-124.	0.6	3
46	Seroprevalence of <sc>SARSâ€™CoVâ€™2</sc> in Parkinson's Disease Patients: A Caseâ€™Control Study. <i>Movement Disorders</i> , 2021, 36, 794-795.	2.2	2
47	Myoclonic dystonia (DYT11) responsive to lacosamide: a case report. <i>Acta Neurologica Belgica</i> , 2022, 122, 1631-1632.	0.5	2
48	Therapeutic Effects of Adrenocorticotrophic Hormone ACTH in Children with Severely Intractable Seizure. <i>Iranian Journal of Child Neurology</i> , 2017, 11, 19-26.	0.2	2
49	Serum leptin levels in Iranian patients with Parkinson's disease. <i>Iranian Journal of Neurology</i> , 2018, 17, 71-77.	0.5	2
50	Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report. <i>Iranian Journal of Neurology</i> , 2018, 17, 91-94.	0.5	2
51	Successful seroconversion following mild COVID-19 contraction in a double-vaccinated B-cell-depleted person with multiple sclerosis: A hint towards booster efficacy?. <i>Neuroimmunology Reports</i> , 2021, 1, 100047.	0.2	2
52	Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103488.	0.9	2
53	Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103664.	0.9	2
54	Manganeseâ€™induced parkinsonism responsive to intranasal insulin: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05562.	0.2	2

#	ARTICLE	IF	CITATIONS
55	Atypical Parkinsonism: Methamphetamine may play a role. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05808.	0.2	2
56	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04712.	0.2	1
57	Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran. <i>Iranian Journal of Neurology</i> , 2018, 17, 6-10.	0.5	1
58	Systemic Sclerosis, Reversible Cerebral Vasoconstriction Syndrome, and NeuroMyelitis Optica in a Patient. <i>Case Reports in Immunology</i> , 2022, 2022, 1-5.	0.2	1
59	Cooccurrence of Chorea-Acanthocytosis and Mesial Temporal Sclerosis: A Possible Role of Caudate Nucleus. <i>Case Reports in Neurological Medicine</i> , 2017, 2017, 1-3.	0.3	0
60	Progressive Parkinsonism With Features of Mitochondrial Disease. <i>JAMA Neurology</i> , 2022, , .	4.5	0
61	Atypical parkinsonism can be a presenting feature of late-onset Huntington's disease. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0